
Claims:

1. Stable solid pharmaceutical composition containing amlodipine or pharmaceutical acceptable salts thereof and bisoprolol or pharmaceutical acceptable salts and pharmaceutically accepted excipients packaged in a damp-proof package and further comprising less than 0.5 % of the compound of the formula



3.

based on the weight of the active ingredients.

2. Pharmaceutical composition according to Claim 1, characterized in that the composition contains amlodipine besylate of pharmaceutically accepted amlodipine salts.

3. Pharmaceutical composition according to Claim 1, characterized in that the composition contains bisoprolol fumarate of pharmaceutically accepted bisoprolol salts.

4. Pharmaceutical composition according to Claim 1, characterized in that the composition contains less than 0.3 % of the compound of the formula (3).

5. Pharmaceutical composition according to Claim 1, characterized in that the composition contains less than 0.2 % of the compound of the formula (3).

6. Packaged solid pharmaceutical composition according to Claim 1, characterized in that the composition is packaged into a cold-formed blister ~~(so-called cold bister /CFF/)~~ of OPA/AL/PVC composite foil covered with an aluminium lidding foil.

7. Packaged solid pharmaceutical composition according to Claim 1, characterized in that the composition is packaged into a blister of thermoformed damp-proof composite foil and covered with an aluminium lidding foil.

8. Packaged solid pharmaceutical composition according to Claim 1, characterized in that the composition is packaged into a glass or polypropylene vessel equipped

with an airtight container cap of polyethylene or polypropylene.

9. The solid pharmaceutical composition form according to any of Claims 1-8 is a tablet or a capsule.

10. Solid pharmaceutical composition form according to Claim 9, which is a tablet packaged in a damp-proof package, characterised in that it comprises 2%-20%, preferably 2%-10%, more preferably, 1-6% of amlodipine base or a pharmaceutically accepted acid addition salt thereof, preferably amlodipine besylate, 2%-20%, preferably 2%-10%, more preferably 1%-6% of bisoprolol fumarate, further comprises 60%-90%, preferably 70%-90%, more preferably 80%-90% of filler, 1%-10%, preferably 4%-6% of disintegrant, 0.5%-3%, preferably 1%-2% of lubricant, 0.3%-2%, preferably 0.5-1 % anti-adhesive, if necessary 1-10 %, preferably 0.1%-5% of binding agent based on the weight of the tablet.

11. Solid pharmaceutical composition according to Claim 1, which is a tablet packaged into a cold-formed blister ~~(so-called cold blister /CFF/)~~ of OPA/AL/PVC composite foil covered with an aluminium lidding foil, or into a blister of thermoformable, damp-proof composite foil and

covered with an aluminium lidding foil, or into a glass or polypropylene vessel equipped with an airtight container cap of polyethylene or polypropylene, comprising 1%-6% of amlodipine besylate, 1%-6% of bisoprolol fumarate, 80%-90% of microcrystalline cellulose, 4%-6% of sodium starch glycolate, 1%-2% of magnesium stearate, 0.5%-1% of colloid silica based on the weight of the tablet.

12. Solid pharmaceutical dosage form according to Claim 1, which is a capsule packaged into a cold-formed blister ~~(so-called cold blister /CFF/)~~ of OPA/AL/PVC composite foil covered with an aluminium lidding foil, or into a blister of thermoformable damp-proof composite foil and covered with an aluminium lidding foil, or into a glass or polypropylene vessel equipped with an airtight container cap of polyethylene or polypropylene, comprising 10%-15% of amlodipine besylate, 10%-15% of bisoprolol fumarate, further 55%-65% of microcrystalline cellulose, 4%-6% of sodium starch glycolate, 1%-2% of magnesium stearate, 0.5%-1% of colloid silica based on the weight of the filling substance of the capsule.

13. Process for the preparation of a stable solid packaged dosage form containing amlodipine and bisoprolol,

characterized in that the amlodipine base or a pharmacutically acceptable salt thereof, the bisoprolol base or a pharmaceutically acceptable salt thereof, a disintegrant, a lubricant and if necessary further excipients used in the pharmaceutical industry are homogenised, then an-anti adhesive is added, the homogenisation is continued, then

a.) the homogenizate is pressed into tablets using a direct compressing process or,

b.) filled into hard gelatine capsules in a known manner,

then the obtained tablets or capsules are packaged into damp-proof protecting packages in a known manner.

14. Process for the preparation of tablets according to Claim 13, characterised in that 2%-20%, preferably 2%-10%, more preferably 1-6% of amlodipine base or a pharmaceutically accepted acid addition salt thereof, preferably amlodipine besylate, 2%-20%, preferably 2%-10%, more preferably 1%-6% of bisoprolol fumarate, further 60%-90%, preferably 70%-90%, more preferably 80%-90% of filler, 1%-10%, preferably 4%-6% of disintegrant, 0.5%-3%, preferably 1%-2% of lubricant, 0.3%-2%, preferably 0.5-1 % anti-adhesive, if necessary

1 %-10 %, preferably 0.5%-1% of binding agent are used based on the weight of the tablets.

15. Process for the preparation of capsules according to Claim 13, characterised in that 5%-80%, preferably 5%-18%, more preferably, 10-15% of amlodipine base or a pharmaceutically accepted acid addition salt thereof, preferably amlodipine besylate, 5%-80%, preferably 5%-15%, more preferably 10%-15% of bisoprolol fumarate, further 1%-10%, preferably 4%-6% of disintegrant, 0.5%-3%, preferably 1%-2% of lubricant, 0.3%-2%, preferably 0.5%-1% of anti-adhesive agent, and if necessary 10%-75%, preferably 45%-75%, more preferably 55%-65% of filler are used based on the weight of the filling substance of the capsule.